Загрузка...
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to these pathways for cancer therapy. Unfortunately, the antitumor activities of single-agent therapies have generally been disappointing...
Сохранить в:
| Опубликовано в: : | Ther Adv Med Oncol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406912/ https://ncbi.nlm.nih.gov/pubmed/26673580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015571111 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|